A Study to Assess the Pharmacokinetics, Effectiveness and Safety of Afimkibart for Induction and Maintenance Therapy in Children With Moderately to Severely Active Crohn's Disease
Abroad (travel likely)RecruitingPHASE3
Conditions
Moderately to Severely Active Crohns Disease
Simple summaryAI-assisted
This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.
Locations
Royal Children's Hospital, Parkville, Victoria, Australia
Perth Children's Hospital, Nedlands, Western Australia, Australia
National Taiwan University Hospital, Taipei, Taiwan
Chulalongkorn University, Bangkok, Thailand
Siriraj Hospital, Bangkok, Thailand
Ramathibodi Hospital, Bangkok, Thailand
Sheffield Childrens Hospital, Sheffield, United Kingdom
Study leads
Clinical Trials
Study Director
Hoffmann-La Roche